Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
Sarepta Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Sarepta Therapeutics's price to sales ratio was 0.9× on Nov 11, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.7× to 13.0×, with a median of 8.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.9× | −0.0 |
| 2025 | Dec 31, 2025 | 0.9× | −6.1 |
| 2024 | Dec 31, 2024 | 7.1× | −1.1 |
| 2023 | Dec 29, 2023 | 8.2× | −4.8 |
| 2022 | Dec 30, 2022 | 13.0× | +1.8 |
| 2021 | Dec 31, 2021 | 11.2× | −16.0 |
| 2020 | Dec 31, 2020 | 27.1× | +0.8 |
| 2019 | Dec 31, 2019 | 26.3× | −0.2 |
| 2018 | Dec 31, 2018 | 26.6× | −8.4 |
| 2017 | Dec 29, 2017 | 35.0× | – |
See a number that looks wrong?